Clinical Trial Update: Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating Ivonescimab as first-line therapy for metastatic Non-Small Cell Lung Cancer in patients with high PD-L1 expression; currentl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Ivonescimab (AK112/SMT112)

Snippet

Sponsor: Summit Therapeutics | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: RECRUITING